TLR4 and Glucose intolerance: Recently, ALA was reported to improve inflammation-induced insulin resistance and glucose intolerance in skeletal cells through blockade the activation of signal transducer and activator of transcription 3 (STAT3) and the abnormal expression of toll-like receptor-4 (TLR4) induced by pro-inflammatory factor interleukin (IL)-617.